Drug intelligence / Profile preview

exbivirumab

Development stage: Discontinued
Lead developer: XTL Biopharmaceuticals
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

Exbivirumab is a monoclonal antibody developed for the treatment of hepatitis B. Its primary mechanism of action is to target the hepatitis B surface antigen (HBsAg), thereby neutralizing the hepatitis B virus and inhibiting its ability to infect liver cells. Exbivirumab has been evaluated for the prevention of hepatitis B virus (HBV) recurrence in liver transplant recipients and is not known to be a biosimilar or generic of any existing antibody[6].

Other names: Libivirumab

Targets

HBsAg (Hepatitis B surface antigen)

Beyond the preview

Go deeper on exbivirumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on exbivirumab.

Explore the full profile